Acetylsalicylic Acid
Nutritional and Metabolic Diseases
University of OsloN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Nutritional and Metabolic Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
USISTAPIDE Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | BB |
Rasburicase Sanofi | Phase 2 | B |
pf-08653945 Pfizer | Phase 2 | CCC |
pf-08653944 Pfizer | Phase 2 | CCC |
CULTIVATED FLAX SEED University of Guadalajara | N/A | D |
View all 9 →
Same molecule, other indications
Acetylsalicylic Acid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →